PubRank

Ena Wang

Author PubWeight™ 182.42‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 A human memory T cell subset with stem cell-like properties. Nat Med 2011 7.47
2 Commensal bacteria control cancer response to therapy by modulating the tumor microenvironment. Science 2013 5.09
3 Serum vascular endothelial growth factor and fibronectin predict clinical response to high-dose interleukin-2 therapy. J Clin Oncol 2009 3.02
4 Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012 2.88
5 Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res 2007 2.69
6 MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010 2.57
7 MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 2010 2.48
8 BACH2 represses effector programs to stabilize T(reg)-mediated immune homeostasis. Nature 2013 2.36
9 Defining the critical hurdles in cancer immunotherapy. J Transl Med 2011 2.32
10 A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat 2011 1.99
11 Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2. Hum Gene Ther 2002 1.96
12 Gene expression profiling of cutaneous wound healing. J Transl Med 2007 1.91
13 IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011 1.90
14 MicroRNA and gene expression patterns in the differentiation of human embryonic stem cells. J Transl Med 2009 1.85
15 Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res 2009 1.81
16 A systematic approach to biomarker discovery; preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". J Transl Med 2008 1.77
17 Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration. Genome Biol 2002 1.74
18 The dual role of IL-10. Trends Immunol 2003 1.72
19 Cancer and inflammation: promise for biologic therapy. J Immunother 2010 1.72
20 Tumors as elusive targets of T-cell-based active immunotherapy. Trends Immunol 2003 1.67
21 Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012 1.61
22 Cytokines and Immune Response in the Tumor Microenvironment. J Immunother (1991) 2001 1.59
23 Transcriptional patterns, biomarkers and pathways characterizing nasopharyngeal carcinoma of Southern China. J Transl Med 2008 1.57
24 Common cancer biomarkers. Cancer Res 2006 1.56
25 Repression of the DNA-binding inhibitor Id3 by Blimp-1 limits the formation of memory CD8+ T cells. Nat Immunol 2011 1.51
26 An immunologic portrait of cancer. J Transl Med 2011 1.50
27 Plerixafor (AMD3100) and granulocyte colony-stimulating factor (G-CSF) mobilize different CD34+ cell populations based on global gene and microRNA expression signatures. Blood 2009 1.46
28 Selection and validation of endogenous reference genes using a high throughput approach. BMC Genomics 2004 1.45
29 Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection. Genome Biol 2007 1.38
30 Enhanced antitumor activity induced by adoptive T-cell transfer and adjunctive use of the histone deacetylase inhibitor LAQ824. Cancer Res 2009 1.38
31 Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors. Cancer Res 2008 1.38
32 Immunobiological characterization of cancer stem cells isolated from glioblastoma patients. Clin Cancer Res 2010 1.37
33 Systemic treatment of xenografts with vaccinia virus GLV-1h68 reveals the immunologic facet of oncolytic therapy. BMC Genomics 2009 1.34
34 Differentiation of two types of mobilized peripheral blood stem cells by microRNA and cDNA expression analysis. J Transl Med 2008 1.33
35 Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med 2005 1.33
36 Emerging concepts in biomarker discovery; the US-Japan Workshop on Immunological Molecular Markers in Oncology. J Transl Med 2009 1.31
37 HCV RNA levels in a multiethnic cohort of injection drug users: human genetic, viral and demographic associations. Hepatology 2012 1.30
38 Quiescent phenotype of tumor-specific CD8+ T cells following immunization. Blood 2004 1.29
39 Polymorphism in clinical immunology - From HLA typing to immunogenetic profiling. J Transl Med 2003 1.28
40 Forecasting the cytokine storm following systemic interleukin (IL)-2 administration. J Transl Med 2004 1.27
41 Workshop on cancer biometrics: identifying biomarkers and surrogates of cancer in patients: a meeting held at the Masur Auditorium, National Institutes of Health. J Immunother 2005 1.25
42 Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005 1.24
43 Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Res 2008 1.22
44 Molecular signatures induced by interleukin-2 on peripheral blood mononuclear cells and T cell subsets. J Transl Med 2006 1.21
45 Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A 2011 1.20
46 Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. Int J Cancer 2011 1.19
47 Chemotherapy enhances vaccine-induced antitumor immunity in melanoma patients. Int J Cancer 2009 1.18
48 Deciphering the molecular machinery of stem cells: a look at the neoblast gene expression profile. Genome Biol 2007 1.18
49 Gene expression profiling in acute allograft rejection: challenging the immunologic constant of rejection hypothesis. J Transl Med 2011 1.15
50 Gene-expression profiling in vaccine therapy and immunotherapy for cancer. Expert Rev Vaccines 2010 1.15
51 TGFβR2 is a major target of miR-93 in nasopharyngeal carcinoma aggressiveness. Mol Cancer 2014 1.15
52 Frequency of MART-1/MelanA and gp100/PMel17-specific T cells in tumor metastases and cultured tumor-infiltrating lymphocytes. J Immunother 2002 1.14
53 A gene expression signature associated with survival in metastatic melanoma. J Transl Med 2006 1.13
54 Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma. Clin Cancer Res 2011 1.10
55 Single-cell network profiling of peripheral blood mononuclear cells from healthy donors reveals age- and race-associated differences in immune signaling pathway activation. J Immunol 2012 1.10
56 Viral-mediated oncolysis is the most critical factor in the late-phase of the tumor regression process upon vaccinia virus infection. BMC Cancer 2011 1.09
57 Genomic scale analysis of racial impact on response to IFN-alpha. Proc Natl Acad Sci U S A 2009 1.08
58 miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. J Transl Med 2010 1.07
59 Functional heterogeneity of vaccine-induced CD8(+) T cells. J Immunol 2002 1.07
60 miR-142-3p prevents macrophage differentiation during cancer-induced myelopoiesis. Immunity 2013 1.07
61 Molecular signatures associated with HCV-induced hepatocellular carcinoma and liver metastasis. PLoS One 2013 1.06
62 Molecular signatures of maturing dendritic cells: implications for testing the quality of dendritic cell therapies. J Transl Med 2010 1.06
63 Concurrent vs sequential adjuvant chemotherapy and hormone therapy in breast cancer: a multicenter randomized phase III trial. J Natl Cancer Inst 2011 1.05
64 Polarized monocyte response to cytokine stimulation. Genome Biol 2005 1.04
65 Inflammatory protein profile during systemic high dose interleukin-2 administration. Proteomics 2006 1.04
66 Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. Clin Cancer Res 2011 1.04
67 Strengths and limitations of laboratory procedures for microRNA detection. Cancer Epidemiol Biomarkers Prev 2010 1.03
68 Melanoma-restricted genes. J Transl Med 2004 1.03
69 Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. J Transl Med 2013 1.03
70 Peritoneal inflammation - A microenvironment for Epithelial Ovarian Cancer (EOC). J Transl Med 2004 1.02
71 Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med 2011 1.02
72 SITC/iSBTc Cancer Immunotherapy Biomarkers Resource Document: online resources and useful tools - a compass in the land of biomarker discovery. J Transl Med 2011 1.02
73 Let-7 microRNAs are developmentally regulated in circulating human erythroid cells. J Transl Med 2009 1.01
74 Gene and microRNA analysis of neutrophils from patients with polycythemia vera and essential thrombocytosis: down-regulation of micro RNA-1 and -133a. J Transl Med 2009 1.00
75 Active-specific immunization against melanoma: is the problem at the receiving end? Semin Cancer Biol 2003 1.00
76 Distinct signatures of the immune responses in low risk versus high risk neuroblastoma. J Transl Med 2011 0.98
77 Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma. Proteomics 2009 0.98
78 Immature monocyte derived dendritic cells gene expression profile in response to Virus-Like Particles stimulation. J Transl Med 2005 0.98
79 Helper B cells promote cytotoxic T cell survival and proliferation independently of antigen presentation through CD27/CD70 interactions. J Immunol 2008 0.97
80 Evaluation of clonal origin of malignant mesothelioma. J Transl Med 2014 0.96
81 Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J Clin Invest 2015 0.96
82 The stable traits of melanoma genetics: an alternate approach to target discovery. BMC Genomics 2012 0.95
83 Translational Medicine is developing in China: a new venue for collaboration. J Transl Med 2011 0.95
84 A genomic- and proteomic-based hypothesis on the eclectic effects of systemic interleukin-2 administration in the context of melanoma-specific immunization. Cells Tissues Organs 2004 0.95
85 Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J Transl Med 2013 0.95
86 Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms. J Transl Med 2005 0.95
87 Gene profiling, biomarkers and pathways characterizing HCV-related hepatocellular carcinoma. J Transl Med 2009 0.95
88 Pancreatic islet cell therapy for type I diabetes: understanding the effects of glucose stimulation on islets in order to produce better islets for transplantation. J Transl Med 2007 0.94
89 Prediction of response to anticancer immunotherapy using gene signatures. J Clin Oncol 2013 0.94
90 HLA associations with nasopharyngeal carcinoma. Curr Mol Med 2009 0.93
91 Gene expression profile of peripheral blood mononuclear cells in response to HIV-VLPs stimulation. BMC Bioinformatics 2008 0.92
92 Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. Am J Pathol 2002 0.91
93 Monocyte/macrophage and T-cell infiltrates in peritoneum of patients with ovarian cancer or benign pelvic disease. J Transl Med 2006 0.91
94 Evaluation of normalization methods for two-channel microRNA microarrays. J Transl Med 2010 0.90
95 TNRC9 downregulates BRCA1 expression and promotes breast cancer aggressiveness. Cancer Res 2013 0.89
96 Activation and propagation of tumor-infiltrating lymphocytes on clinical-grade designer artificial antigen-presenting cells for adoptive immunotherapy of melanoma. J Immunother 2014 0.89
97 Potency analysis of cellular therapies: the emerging role of molecular assays. J Transl Med 2007 0.88
98 Chromosomal imbalances in nasopharyngeal carcinoma: a meta-analysis of comparative genomic hybridization results. J Transl Med 2006 0.88
99 The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness. Clin Cancer Res 2005 0.88
100 High-dimensional analysis of the aging immune system: verification of age-associated differences in immune signaling responses in healthy donors. J Transl Med 2014 0.87
101 Tumor escape and progression of HER-2/neu negative breast cancer under immune pressure. J Transl Med 2011 0.87
102 15 kDa Granulysin versus GM-CSF for monocytes differentiation: analogies and differences at the transcriptome level. J Transl Med 2011 0.87
103 Comparative analysis of peritoneum and tumor eicosanoids and pathways in advanced ovarian cancer. Clin Cancer Res 2007 0.87
104 Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med 2012 0.87
105 Damage associated molecular pattern molecule-induced microRNAs (DAMPmiRs) in human peripheral blood mononuclear cells. PLoS One 2012 0.87
106 GM-CSF/IL-3/IL-5 receptor common beta chain (CD131) expression as a biomarker of antigen-stimulated CD8+ T cells. J Transl Med 2008 0.86
107 Infectious pathogen detection arrays: viral detection in cell lines and postmortem brain tissue. Biotechniques 2005 0.86
108 IRF5 gene polymorphisms in melanoma. J Transl Med 2012 0.86
109 Induction of pro-inflammatory programs in enteroendocrine cells by the Toll-like receptor agonists flagellin and bacterial LPS. Int Immunol 2008 0.86
110 Gene expression signatures of interleukin-2 in vivo and in vitro and their relation to anticancer therapy. Crit Rev Immunol 2007 0.86
111 Associations between HLA class I alleles and the prevalence of nasopharyngeal carcinoma (NPC) among Tunisians. J Transl Med 2007 0.86
112 Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments. J Transl Med 2011 0.85
113 Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J Transl Med 2009 0.85
114 Quality controls in cellular immunotherapies: rapid assessment of clinical grade dendritic cells by gene expression profiling. Mol Ther 2012 0.85
115 Evaluation of gene expression profiles of immature dendritic cells prepared from peripheral blood mononuclear cells. Transfusion 2008 0.85
116 Cytokine polymorphism and its possible impact on cancer. Immunol Res 2004 0.85
117 Permissivity of the NCI-60 cancer cell lines to oncolytic Vaccinia Virus GLV-1h68. BMC Cancer 2011 0.85
118 Systems biology applied to vaccine and immunotherapy development. BMC Syst Biol 2011 0.85
119 Influence of quercetin-rich food intake on microRNA expression in lung cancer tissues. Cancer Epidemiol Biomarkers Prev 2012 0.84
120 Racial differences in B cell receptor signaling pathway activation. J Transl Med 2012 0.84
121 The role of quantitative PCR for the immune monitoring of cancer patients. Expert Opin Biol Ther 2002 0.84
122 Molecular immune signatures of HIV-1 vaccines in human PBMCs. FEBS Lett 2009 0.83
123 Migration deficit in monocyte-macrophages in human ovarian cancer. Cancer Immunol Immunother 2007 0.83
124 Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opin Biol Ther 2014 0.82
125 CD4+ T cells inhibit the neu-specific CD8+ T-cell exhaustion during the priming phase of immune responses against breast cancer. Breast Cancer Res Treat 2010 0.82
126 Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells. Proteomics 2011 0.81
127 Melanoma NOS1 expression promotes dysfunctional IFN signaling. J Clin Invest 2014 0.81
128 DNA array-based gene profiling in tumor immunology. Clin Cancer Res 2004 0.81
129 Comprehensive epitope mapping of the Epstein-Barr virus latent membrane protein-2 in normal, non tumor-bearing individuals. Cancer Immunol Immunother 2006 0.80
130 Metastatic lesions with and without interleukin-18-dependent genes in advanced-stage melanoma patients. Am J Pathol 2013 0.80
131 The modulation of hepatitis C virus 1a replication by PKR is dependent on NF-kB mediated interferon beta response in Huh7.5.1 cells. Virology 2013 0.80
132 Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. J Transl Med 2014 0.80
133 Global transcriptional analysis for biomarker discovery and validation in cellular therapies. Mol Diagn Ther 2009 0.79
134 Timing and intensity of exposure to interferon-γ critically determines the function of monocyte-derived dendritic cells. Immunology 2014 0.79
135 The international effort: building the bridge for Translational Medicine: Report of the 1st International Conference of Translational Medicine (ICTM). Clin Transl Med 2012 0.79
136 Quality assessment of cellular therapies: the emerging role of molecular assays. Korean J Hematol 2010 0.79
137 18th Annual Scientific Meeting of the International Society for Biological Therapy of Cancer. 30 October-2 November 2003, Bethesda, Maryland, USA. Expert Opin Biol Ther 2004 0.79
138 Development and promotion in translational medicine: perspectives from 2012 sino-american symposium on clinical and translational medicine. Clin Transl Med 2012 0.78
139 The transcription factor BACH2 promotes tumor immunosuppression. J Clin Invest 2016 0.78
140 Mechanism of immune response during immunotherapy. Yonsei Med J 2004 0.78
141 Stem cells in melanoma development. Cancer Lett 2008 0.78
142 Transcriptional analysis of tumor-specific T-cell responses in cancer patients. Crit Rev Immunol 2002 0.77
143 Characterization of CD8(-) HLA class I/epitope tetrameric complexes binding T cells. J Immunother 2002 0.77
144 Tumor-induced CD11b(+) Gr-1(+) myeloid-derived suppressor cells exacerbate immune-mediated hepatitis in mice in a CD40-dependent manner. Eur J Immunol 2015 0.77
145 Analysis of vaccine-induced T cells in humans with cancer. Adv Exp Med Biol 2010 0.77
146 Multiparametric analyses of human PBMCs loaded ex vivo with a candidate idiotype vaccine for HCV-related lymphoproliferative disorders. PLoS One 2012 0.77
147 Correlates between host and viral transcriptional program associated with different oncolytic vaccinia virus isolates. Hum Gene Ther Methods 2012 0.77
148 Complementary techniques: RNA amplification for gene profiling analysis. Adv Exp Med Biol 2007 0.77
149 The National Institutes of Health Center for Human Immunology, Autoimmunity, and Inflammation: history and progress. Ann N Y Acad Sci 2013 0.77
150 Corrigendum: Effects of Systemically Administered Hydrocortisone on the Human Immunome. Sci Rep 2016 0.76
151 Inherent transcriptional signatures of NK cells are associated with response to IFNα + rivabirin therapy in patients with Hepatitis C Virus. J Transl Med 2015 0.76
152 Inter-donor variation in cell subset specific immune signaling responses in healthy individuals. Am J Clin Exp Immunol 2012 0.76
153 A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. J Transl Med 2012 0.76
154 Tumor microenvironment and the immune response. Surg Oncol Clin N Am 2007 0.76
155 Correction: Baseline Levels and Temporal Stability of 27 Multiplexed Serum Cytokine Concentrations in Healthy Subjects. PLoS One 2015 0.75
156 "Sequencing-grade" screening for BRCA1 variants by oligo-arrays. J Transl Med 2008 0.75
157 Association between HRAS rs12628 and rs112587690 polymorphisms with the risk of melanoma in the North American population. Med Oncol 2012 0.75
158 Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? J Proteome Res 2011 0.75
159 Overview of melanoma vaccines and promising approaches. Curr Oncol Rep 2004 0.75
160 Vaccination with T cell-defined antigens. Expert Opin Biol Ther 2004 0.75
161 Tumor microenvironment: what have we learned studying the immune response in this puzzling battlefield? Tumori 2003 0.75